KDMN - Kadmon Holdings, Inc.

NYSE - NYSE Delayed Price. Currency in USD
5.14
+0.29 (+5.98%)
At close: 4:02PM EST

5.20 +0.06 (1.17%)
Pre-Market: 6:19AM EST

Stock chart is not supported by your current browser
Previous Close4.85
Open4.86
Bid5.14 x 4000
Ask5.20 x 1800
Day's Range4.83 - 5.26
52 Week Range1.63 - 5.38
Volume5,416,616
Avg. Volume1,808,163
Market Cap820.298M
Beta (5Y Monthly)2.46
PE Ratio (TTM)N/A
EPS (TTM)-0.75
Earnings DateAug 04, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.80
  • 3 Healthcare Stocks With Important Catalysts in Q1
    TipRanks

    3 Healthcare Stocks With Important Catalysts in Q1

    Blink, and you might just miss it. We are referring to the colossal gains that can be achieved by a select group of stocks in almost no time at all, namely those inhabiting the healthcare sector. But how is it that these types of investments can reach such heights overnight? The answer, as it turns out, is related to the nature of the industry itself.Unlike other names, these companies count on only a few vital indicators like the release of data or FDA rulings. As a result, a single update can act as a catalyst, with the power to rapidly catapult shares in either direction. This volatility and the risk that come with it can be enough to ward off some investors. For others, these stocks represent some of the most captivating growth plays the Street has to offer.Based on this, seasoned Street veterans argue that the right time to snap up shares of a healthcare name might just be ahead of key catalysts. However, once a potential portfolio addition has been identified, it isn’t always easy to determine if it’s the most compelling investment. That’s where TipRanks comes in.Taking advantage of TipRanks' Stock Screener tool, we were able to find out what Wall Street analysts are saying about 3 healthcare stocks as they approach important catalysts in the first quarter. Not only is the analyst community bullish, with each earning a Strong Buy consensus rating, but the stocks also boast substantial upside potential from current levels. Let’s jump right in.Karyopharm Therapeutics (KPTI)Karyopharm Therapeutics’ primary goal is to develop treatments that will help patients in their battles against cancer. Thanks to its innovative oral Selective Inhibitor of Nuclear Export (SINE) technology, its products could potentially inhibit Exportin 1 (XPO1), a protein that decreases the body’s ability to defend against tumors.With Phase 3 BOSTON study data for its Selinexor (Xpovio) drug scheduled for release this quarter, Wall Street’s focus has shifted towards KPTI. The therapy, which has already been approved for relapsed or refractory multiple myeloma (RRMM) treatment in patients that have received at least four previous therapies, is being evaluated for use in earlier lines of treatment. Specifically, the BOSTON study will provide data on its ability to treat patients with multiple myeloma who have already received one to three lines of therapy.J.P. Morgan analyst Eric Joseph tells clients that he expects a favorable outcome based on its SVd performance in the Phase 1b/2 STOMP study and the control Vd regimen’s previous performance. On top of this, the four-star analyst noted that the FDA’s statements about Xpovio’s accelerated approval in July as well as physician experience with SVd support this conclusion. While he did acknowledge that the readout window does create some risk, he wrote in a note to clients that “current levels still reflect overly cautious risk assumptions for BOSTON against a base case peak sales opportunity.”In line with this bullish thesis, Joseph maintained an Overweight rating in addition to increasing the price target by $4. At the new $27 price target, shares could surge 54% in the next twelve months. (To watch Joseph’s track record, click here)In general, the rest of the Street is on the same page. 5 Buys and a single Hold add up to a Strong Buy analyst consensus. Additionally, the $25.60 average price target puts the upside potential at 46%. (See Karyopharm stock analysis on TipRanks)Kala Pharmaceuticals (KALA)Switching gears now, Kala Therapeutics is focused on treatments for eye diseases. Due to its proprietary mucus-penetrating particle (MPP) technology, the analyst community has been keeping tabs on this biopharma.After the company received a complete response letter (CRL) for the KPI-121 0.25% (EYSUVIS) NDA, its Dry Eye Disease therapy, the upcoming Phase 3 STRIDE 3 trial top-line data readout has attracted significant attention as this data will be used in its CRL response. Management stated that they have decreased the patient variability in STRIDE 3 that led to missing statistical significance for ocular pain in the STRIDE 2 Phase 3 trial. With the readout expected sometime from late February to the end of March, an NDA could be resubmitted in the first half of 2020, should the results be positive.For Wedbush’s Liana Moussatos, the large market opportunity is enough to get her on board. “We estimate that in 2027 gross annual sales for KPI-121 0.25% could reach about $1.89 billion for Dry Eye Disease. We project full year profitability in 2021 with about $173 million in revenues in 2021 (~$87 million for Dry Eye and ~$86 million for Post-Surgical Inflammation and Pain),” she commented. As KALA represents a “buying opportunity”, she reiterated her Outperform call. Most noteworthy, however, is her $51 price target, which is the highest on the Street and suggests 694% upside potential. (To watch Moussatos’ track record, click here)While not nearly as aggressive as Moussatos, Oppenheimer analyst Esther Rajavelu is still very much in favor of KALA. “We maintain our Outperform rating as we believe Eysuvis (if approved) may address significant unmet needs in the nascent dry eye disease market, which we estimate could be a $3B US market opportunity. We remain positively skewed on STRIDE-3 readout anticipated in 1Q20, as the changes in trial inclusion/exclusion criteria could meaningfully increase the probability of success,” she explained. Based on this assumption and the lower operating expenses, the analyst increased the price target from $9 to $12 along with her bullish call. (To watch Rajavelu’s track record, click here)Looking at the consensus breakdown, the rest of the Street also has high hopes. A Strong Buy consensus rating breaks down into 3 Buys and 1 Hold assigned in the last three months. Not to mention the $19.75 average price target implies 208% upside potential. (See Kala stock analysis on TipRanks)Kadmon Holdings (KDMN)With a proven track record of successful drug development, Kadmon Holdings wants to offer cutting-edge medicines for immune and fibrotic diseases as well as immuno-oncology therapies. As it prepares for a Pivotal trial data readout for its late-stage candidate, KD025, in chronic graft-versus-host disease (cGVHD), some think that 2020 could be a big year for KDMN.Analysts are even more excited about the company’s prospects after it was announced that INCY’s candidate itacitinib failed to meet its Phase 3 endpoint for treatment-naive acute GVHD. Cantor Fitzgerald’s Eliana Merle argues that the itacitinib setback indicates significant commercial upside for Kadmon’s candidate and supports its safety profile.“We think KD025's differentiation on safety/tolerability could be a key driver of longer duration of use (and ultimate market opportunity),” the analyst stated. On top of this, she believes that the design of KD025’s trial lends itself to a favorable outcome. Itacitnib was evaluated in the acute steroid-naive setting, which makes it more difficult to achieve a successful result, while KD025 was studied in the steroid-refractory chronic environment.Merle added, “We continue to see the cGHVD market opportunity as underappreciated for KDMN's KD025. We model $500 million in U.S. peak sales and we see INCY's update as supportive of this opportunity.”It makes sense, then, that the analyst stayed with the bulls, leaving the Overweight rating and $10 price target unchanged. Should the target be met, a 118% twelve-month gain could be in the cards. (To watch Merle’s track record, click here)What do other Wall Street pros think? As 100% of the analysts that have published a review in the last three months were bullish, the word on the Street is that KDMN is a Strong Buy. With a $13.25 average price target, the upside potential comes in at 189%. (See Kadmon stock analysis on TipRanks)

  • ACCESSWIRE

    Kadmon Announces Acceptance of Late-Breaking Abstract of KD025 for cGVHD at the 2020 TCT Meetings

    NEW YORK, NY / ACCESSWIRE / January 10, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that expanded data from the interim analysis of ROCKstar (KD025-213), its ongoing pivotal trial of KD025 ...

  • Investors Who Bought Kadmon Holdings (NYSE:KDMN) Shares A Year Ago Are Now Up 90%
    Simply Wall St.

    Investors Who Bought Kadmon Holdings (NYSE:KDMN) Shares A Year Ago Are Now Up 90%

    The simplest way to invest in stocks is to buy exchange traded funds. But investors can boost returns by picking...

  • Implied Volatility Surging for Kadmon (KDMN) Stock Options
    Zacks

    Implied Volatility Surging for Kadmon (KDMN) Stock Options

    Investors need to pay close attention to Kadmon (KDMN) stock based on the movements in the options market lately.

  • ACCESSWIRE

    Kadmon and Meiji Announce Collaboration to Develop and Commercialize KD025 in Japan

    NEW YORK, NY and TOKYO, JAPAN / ACCESSWIRE / December 26, 2019 / Kadmon Holdings, Inc. (KDMN), a New York-based biopharmaceutical company, and Meiji Seika Pharma Co., Ltd, a Tokyo-based wholly owned subsidiary of Meiji Holdings Co., Ltd. (TYO:2269), today announced that the companies have entered into a strategic collaboration to form a joint venture to exclusively develop and commercialize KD025 in Japan and certain other Asian countries. Under the terms of the transaction agreements, Kadmon will receive payments which could exceed $29.0 million, resulting from various potential establishment, development, regulatory and commercial milestones. In addition, Kadmon is eligible to receive double-digit percentage royalty payments on sales of KD025 in the territory.

  • Hedge Funds Have Never Been More Bullish On Kadmon Holdings, Inc. (KDMN)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Kadmon Holdings, Inc. (KDMN)

    "The global economic environment is very favorable for investors. Economies are generally strong, but not too strong. Employment levels are among the strongest for many decades. Interest rates are paused at very low levels, and the risk of significant increases in the medium term seems low. Financing for transactions is freely available to good borrowers, […]

  • Benzinga

    The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

    Biotech stocks went back and forth but managed to end the week with a gain. As usual, some stocks swung wildly in reaction to catalysts, primarily clinical readouts. Aurinia Pharmaceuticals Inc (NASDAQ: ...

  • ACCESSWIRE

    Kadmon to Present Updated Data from Phase 2 Study of KD025 in cGVHD at the 61st ASH Annual Meeting & Exposition

    NEW YORK, NY / ACCESSWIRE / December 3, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that longer-term follow-up results from KD025-208, its ongoing Phase 2 study of KD025 in chronic graft-versus-host ...

  • Largest Insider Trades of the Week
    GuruFocus.com

    Largest Insider Trades of the Week

    Insiders load up on Energy Transfer, dump Invitation Homes shares Continue reading...

  • ACCESSWIRE

    Kadmon Announces Closing of $101.6mm Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

    NEW YORK, NY / ACCESSWIRE / November 18, 2019 / Kadmon Holdings, Inc. (KDMN) today announced the closing of its previously announced underwritten public offering of 29,900,000 shares of common stock for gross proceeds of $101.6 million, before deducting underwriting discounts and estimated offering expenses, which includes the full exercise of the underwriters' option to purchase additional shares. Kadmon intends to use the net proceeds from the offering for the clinical development of its lead product candidates, discovery, research and preclinical studies of its other product candidates, and other general corporate purposes. The securities described above were offered by Kadmon pursuant to a shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission (the "SEC") on September 24, 2019.

  • ACCESSWIRE

    Kadmon to Participate in Upcoming Investor Conferences

    NEW YORK, NY / ACCESSWIRE / November 18, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the following investor ...

  • ACCESSWIRE

    Kadmon Announces Pricing of Public Offering of Common Stock

    The gross proceeds to Kadmon from the Offering, before deducting underwriting discounts and commissions and other estimated expenses payable by Kadmon, are expected to be $88.4 million. In addition, Kadmon has granted the underwriters in the Offering a 30-day option to purchase up to an additional 3,900,000 shares of Kadmon's common stock on the same terms and conditions as the shares offered in the Offering.

  • ACCESSWIRE

    Kadmon Announces Proposed Public Offering of Common Stock

    Kadmon also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering on the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

  • Benzinga

    The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 11) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Agenus Inc ...

  • ACCESSWIRE

    Kadmon Announces that KD025 Met Primary Endpoint at Interim Analysis of Pivotal Trial in Chronic Graft-Versus-Host Disease

    NEW YORK / ACCESSWIRE / November 11, 2019 / Kadmon Holdings, Inc. (KDMN) today announced positive topline results from the planned interim analysis of ROCKstar (KD025-213), the fully enrolled pivotal trial evaluating KD025 in patients with chronic graft-versus-host disease (cGVHD) who have received at least two prior lines of systemic therapy. The trial met the primary endpoint of Overall Response Rate (ORR) at the interim analysis, which was conducted as scheduled two months after completion of enrollment.

  • Hedge Funds Have Never Been More Bullish On Kadmon Holdings, Inc (KDMN)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Kadmon Holdings, Inc (KDMN)

    It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]

  • ACCESSWIRE

    Kadmon Establishes Strategic Partnership with BioNova to Develop and Commercialize KD025 for the Treatment of GVHD in China

    NEW YORK, NY / ACCESSWIRE / November 7, 2019 / Kadmon Holdings, Inc. (KDMN) today announced a strategic partnership with BioNova Pharmaceuticals Ltd. (BioNova) to form a joint venture to exclusively develop and commercialize KD025 for the treatment of graft-versus-host disease (GVHD) in the People's Republic of China. KD025, Kadmon's lead product candidate, is a ROCK2 inhibitor in a pivotal clinical trial in the United States for the treatment of chronic graft-versus-host disease (cGVHD).

  • ACCESSWIRE

    Kadmon Provides Business Update and Reports Third Quarter 2019 Financial Results

    NEW YORK, NY / ACCESSWIRE / November 7, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today provided a business update and reported financial and operational results for the third quarter of 2019. "Following ...

  • ACCESSWIRE

    Kadmon Announces FDA Approval of CLOVIQUE (TM), A Room-Temperature Stable Trientine Hydrochloride Product

    NEW YORK, NY / ACCESSWIRE / October 21, 2019 / Kadmon Holdings, Inc. (KDMN) today announced that the U.S. Food and Drug Administration (FDA) has approved CLOVIQUE™ (Trientine Hydrochloride Capsules, USP), a room-temperature stable, branded generic product. Trientine hydrochloride is used for the treatment of Wilson's disease in patients who are intolerant of penicillamine.

  • Does Kadmon Holdings, Inc.'s (NYSE:KDMN) CEO Salary Compare Well With Others?
    Simply Wall St.

    Does Kadmon Holdings, Inc.'s (NYSE:KDMN) CEO Salary Compare Well With Others?

    Harlan Waksal became the CEO of Kadmon Holdings, Inc. (NYSE:KDMN) in 2014. This report will, first, examine the CEO...

  • ACCESSWIRE

    Kadmon Announces Sale of 1.4 Million Shares of MeiraGTx Holdings plc

    NEW YORK, NY / ACCESSWIRE / October 3, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the Company has entered into a transaction to divest approximately 1.4 million shares of MeiraGTx Holdings ...

  • ACCESSWIRE

    Kadmon Announces FDA Approval of Generic Trientine Hydrochloride

    NEW YORK, NY / ACCESSWIRE / September 17, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the U.S. Food and Drug Administration (FDA) has approved its generic Trientine Hydrochloride Capsules ...

  • 3 Biotech Stocks That Could Double Your Money
    Motley Fool

    3 Biotech Stocks That Could Double Your Money

    Hardly anyone's heard of these drugmakers, but some analysts think they could be top performers.